Skip to main navigation Skip to search Skip to main content

Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report

  • Amsterdam UMC - University of Amsterdam
  • Amsterdam UMC

Research output: Contribution to journalArticleAcademicpeer-review

44 Downloads (Pure)

Abstract

Enteroviruses can cause severe, chronic infections in patients with primary and secondary humoral immunodeficiencies. These patients may benefit from anti-enteroviral therapy. Here, we report a patient with mantle cell lymphoma treated with chemotherapy followed by autologous stem cell transplantation and rituximab maintenance therapy, who presented with echovirus 7-associated deafness and myositis leading to severe disability. She showed marked clinical improvement and enterovirus clearance from faeces and blood after treatment with intravenous immunoglobulins (IVIgs) followed by remdesivir. We demonstrated efficacy of IVIg and remdesivir against echovirus 7 using virus neutralization and cell culture assays, which supports a potential contribution to the treatment success for both therapies.
Original languageEnglish
Article number13596535251385624
JournalAntiviral therapy
Volume30
Issue number5
DOIs
Publication statusPublished - 30 Sept 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • antiviral treatment
  • case report
  • enterovirus
  • immunocompromised host

Fingerprint

Dive into the research topics of 'Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report'. Together they form a unique fingerprint.

Cite this